Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex

Status Completed

Clinical Trial Summary

This study aims to assess a fixed-dose regimen of activated prothrombin complex concentrate (FEIBA VH, Baxter) versus the variable, manufacturer recommended, dose regimen of inactivated prothrombin complex concentrate (Kcentra, CSL Behring) for reversal of warfarin-associated major hemorrhage.

Clinical Trial Description

Warfarin, a vitamin K antagonist (VKA), is the most frequently prescribed oral anticoagulant. Warfarin-associated major hemorrhage occurs at a rate of 1.7% to 3.4% in routine clinical practice and warrants rapid reversal of anticoagulation by correcting supratherapeutic international normalized ratio (INR) values.

Warfarin inhibits synthesis of vitamin K dependent coagulation factors II, VII, IX, and X, and strategies for reversal of warfarin-associated coagulopathy are aimed at restoring deficient factors. Four-factor prothrombin complex concentrates (PCCs) contain the coagulation factors which warfarin inhibits and are an attractive option for rapid reversal due to ease of reconstitution and no requirement for blood-type matching.

Manufacturer dosing recommendations exist for PCCs based on patient weight, baseline INR, and target INR, but studies have suggested fixed dosing strategies in an effort to determine the most efficacious dose for VKA-reversal while sparing adverse events. These studies have also utilized different PCC formulations, with some studies utilizing 4-factor activated PCC (aPCC), which denotes product containment of factor VII in an activated state.

In the United States, product availability is limited to a single 4-factor aPCC (FEIBA VH, Baxter) indicated for hemophilia patients with inhibitors and a single 4-factor inactivated PCC (Kcentra, CSL Behring) approved for VKA-reversal. Various institutions choose to utilize off-label fixed dosing strategies of 4-factor aPCC in an effort to administer the lowest possible dose to reverse VKAs, while others utilize manufacturer recommended dosing of 4-factor inactivated PCC. ;

Study Design

Related Conditions & MeSH terms

Hemorrhage

Clinical Trial Details

NCT number	NCT02565836
Study type	Observational
Source	Rush University Medical Center
Contact
Status	Completed
Phase	N/A
Start date	October 2015
Completion date	September 30, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02815670` - Reversal Dabigatran Anticoagulant Effect With Idarucizumab	Phase 3
Completed	`NCT04588350` - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery	N/A
Recruiting	`NCT02972385` - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed	`NCT02554006` - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings	N/A
Completed	`NCT02569606` - Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
Recruiting	`NCT02446730` - Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome	Phase 4
Completed	`NCT01935427` - Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume	N/A
Completed	`NCT01955720` - Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran	Phase 1
Recruiting	`NCT01709786` - Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage	N/A
Completed	`NCT01191554` - Dose-ranging Study of Tranexamic Acid in Valve Surgery	N/A
Completed	`NCT01210417` - Trauma Heart to Arm Time	N/A
Completed	`NCT01136590` - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery	Phase 4
Completed	`NCT01085006` - The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery	Phase 1/Phase 2
Completed	`NCT00700141` - Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®	N/A
Completed	`NCT00375466` - Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.	N/A
Completed	`NCT00147420` - RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet	N/A
Completed	`NCT00479362` - Anticoagulant Therapy During Pacemaker Implantation	Phase 4
Recruiting	`NCT05945680` - Tranexamic Acid in Breast Esthetic Surgery.	Phase 4
Completed	`NCT03273322` - Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure	Phase 2/Phase 3
Withdrawn	`NCT05672407` - The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms